IGI Laboratories, Inc. (IG) said it has submitted an additional abbreviated new drug application, or ANDA, to the FDA, bringing the company's total number of submissions to six.
IGI President and CEO Charlie Moore commented, "Our team has done a tremendous job in effectively managing our development projects. We have built a strong development group, and the team now has six ANDA filings with the US FDA.
We expect to file three-to-five additional ANDAs in 2012, which will bring our total of ANDA submissions to nine to eleven by the end of 2012." The development of ANDA products has successfully been integrated into the company's ongoing contract services business.
For comments and feedback: editorial@rttnews.com